FDG-PET and beyond: molecular breast cancer imaging.
暂无分享,去创建一个
[1] Sanjiv Sam Gambhir,et al. Positron emission tomography in diagnosis and management of invasive breast cancer: current status and future perspectives. , 2003, Clinical breast cancer.
[2] C. Kao,et al. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases. , 2000, Anticancer research.
[3] Barry A. Siegel,et al. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] J C Rosenwald,et al. CT and (18)F-deoxyglucose (FDG) image fusion for optimization of conformal radiotherapy of lung cancers. , 2001, International journal of radiation oncology, biology, physics.
[5] H. Moch,et al. Is positron emission tomography an accurate non-invasive alternative to sentinel lymph node biopsy in breast cancer patients? , 2003, Journal of the National Cancer Institute.
[6] N. Cascinelli,et al. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management. , 2001, Journal of the National Cancer Institute.
[7] S. Gambhir. Molecular imaging of cancer with positron emission tomography , 2002, Nature Reviews Cancer.
[8] J. Carreras,et al. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers. , 2002, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.
[9] A. Kortt,et al. Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting. , 2001, Biomolecular engineering.
[10] V. Lowe,et al. Positron emission tomography and sentinel lymph node dissection in breast cancer. , 2002, Clinical breast cancer.
[11] J. Bergh,et al. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] R. Sutherland,et al. Effects of oestrogens on cell proliferation and cell cycle kinetics. A hypothesis on the cell cycle effects of antioestrogens. , 1983, European journal of cancer & clinical oncology.
[13] D. Mankoff,et al. Evaluation of the Internal Mammary Lymph Nodes by FDG-PET in Locally Advanced Breast Cancer (LABC) , 2004, American journal of clinical oncology.
[14] J L Sunshine,et al. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. , 1993, Radiology.
[15] Gerald Reischl,et al. PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[16] S R Cherry,et al. Design and evaluation of an LSO PET detector for breast cancer imaging. , 2000, Medical physics.
[17] S. Yang,et al. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer , 2002, Journal of Cancer Research and Clinical Oncology.
[18] M. Greco,et al. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[19] A. Lammertsma,et al. Determinants of Diagnostic Performance Of [F-18]Fluorodeoxyglucose Positron Emission Tomography for Axillary Staging in Breast Cancer , 2002, Annals of surgery.
[20] Claudio Landoni,et al. PET/CT and breast cancer , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[21] Mark Muzi,et al. Positron emission tomography imaging of brain tumors. , 2003, Neuroimaging clinics of North America.
[22] C. Kao,et al. Fluorine-18 FDG-PET in Detecting Local Recurrence and Distant Metastases in Breast Cancer—Taiwanese Experiences , 2002, Cancer investigation.
[23] Michael J. Welch,et al. Positron emission tomographic assessment of ”metabolic flare” to predict response of metastatic breast cancer to antiestrogen therapy , 1999, European Journal of Nuclear Medicine.
[24] Cyrill Burger,et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. , 2003, International journal of radiation oncology, biology, physics.
[25] V. Bettinardi,et al. Value of integrated PET/CT for lesion localisation in cancer patients: a comparative study , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[26] R. Sutherland,et al. Tamoxifen stimulation of human breast cancer cell proliferation in vitro: a possible model for tamoxifen tumour flare. , 1984, European journal of cancer & clinical oncology.
[27] L. Adler,et al. Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET. , 1997, Radiology.
[28] R L Wahl,et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Robert B Livingston,et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[30] M. Mintun,et al. Positron Tomographic Assessment of 16α-[18F] Fluoro-17β-Estradiol Uptake in Metastatic Breast Carcinoma , 1991 .
[31] M. Schwaiger,et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] A. Wu,et al. Designer genes: recombinant antibody fragments for biological imaging. , 2000, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.
[33] M. Tatsumi,et al. Comparison of FDG-PET with MIBI-SPECT in the detection of breast cancer and axillary lymph node metastasis. , 2000, Journal of computer assisted tomography.
[34] P F Sharp,et al. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] P. Sharp,et al. Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. , 1998, Annals of surgery.
[36] X. Setoain,et al. 99mTc-MDP bone scintigraphy and 18F-FDG positron emission tomography in lung and prostate cancer patients: different affinity between lytic and sclerotic bone metastases , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[37] Rainer Linke,et al. 18F-FDG PET and 99mTc-sestamibi scintimammography for monitoring breast cancer response to neoadjuvant chemotherapy: a comparative study , 2001, European Journal of Nuclear Medicine.
[38] A. Pecking,et al. Detection of occult disease in breast cancer using fluorodeoxyglucose camera-based positron emission tomography. , 2001, Clinical breast cancer.
[39] H. Schirrmeister,et al. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures , 2001, European Journal of Nuclear Medicine.
[40] D. Mankoff,et al. 18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] David J. Yang,et al. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[42] J. Nährig,et al. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] Michael E Phelps,et al. Relationship between 18F-FDG uptake and breast density in women with normal breast tissue. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[44] Pauwels,et al. The Place of Whole-Body PET FDG for the Diagnosis of Distant Recurrence of Breast Cancer. , 2000, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.
[45] H. Biersack,et al. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumours , 1997, European Journal of Nuclear Medicine.
[46] D. Mankoff,et al. Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. , 2002, Academic radiology.
[47] S. Yasuda,et al. Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy , 2001, Nuclear medicine communications.
[48] M. Welch,et al. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] H. Moch,et al. Selective Axillary Surgery in Breast Cancer Patients Based on Positron Emission Tomography with 18F-Fluoro-2-Deoxy-D-Glucose: not Yet! , 2004, Breast Cancer Research and Treatment.
[50] P A Salvadori,et al. Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients. , 2000, Clinical breast cancer.
[51] C. Goldsmith,et al. A Prospective Evaluation of Positron Emission Tomography Scanning, Sentinel Lymph Node Biopsy, and Standard Axillary Dissection for Axillary Staging in Patients with Early Stage Breast Cancer , 2004, Annals of Surgical Oncology.